Browse the evidence

Glucagon-like peptide 1 receptor agonists hold great promise to reverse some cancer risk in people living with obesity.

GLP-1 receptor agonists may be considered in obesity management to potentially reduce cancer risk.

Endoluminal bariatric and metabolic therapies have expanded significantly, with FDA-approved therapies available for patients with a body mass index as high as 50 kg/m².

Practitioners should consider these therapies for patients with high BMI who may not qualify for traditional bariatric surgery.

Obesity management requires understanding both genetic and environmental components.

Practitioners should consider both genetic and lifestyle factors in obesity treatment.

Lifestyle interventions can help in the prevention and treatment of obesity by altering epigenetic signatures.

Encouraging lifestyle changes can be an effective strategy in obesity treatment.

There are no significant differences in muscle mass and strength gains between consuming protein three or five times a day.

Practitioners can advise that both three and five protein meals are effective for muscle gain.

Adherence to recommended dosage and seeking medical advice regarding possible side effects/interactions is recommended.

Practitioners should advise patients to follow dosage guidelines and consult healthcare providers.

Liraglutide reduced global eating disorder risk scores.

Practitioners may consider liraglutide as a treatment option for reducing eating disorder risk in patients with obesity or Type 2 diabetes.

Food cravings improved or remained unchanged following liraglutide and semaglutide treatment.

Practitioners should be aware that while some patients may experience reduced cravings, others may not see changes.

PAP+semaglutide was associated with lower incident pulmonary hypertension (PH) at 1 year (RR:0.45) and at 3 years (RR:0.50), and lower mortality at 1 year (RR:0.35) and 3 years (RR:0.37).

Incorporating GLP-1 receptor agonists like semaglutide may enhance treatment outcomes for obese patients with OSA on PAP.

Maximum strength increased marginally significantly by 4.6 kg during the intervention.

Practitioners can expect modest strength improvements with low-intensity training in this population.

Creatine supplementation demonstrated non-significant effects on muscle strength (SMD = 0.03, 95% CI: -0.35, 0.42) but yielded the most pronounced improvement in muscle mass (MD = 2.18, 95% CI: 0.92, 3.44).

Creatine may be beneficial for increasing muscle mass in older adults, but its effect on strength is not significant.

The weekend warrior (WW) physical activity pattern is associated with significantly lower odds of sarcopenia compared to regularly active (RA) individuals (OR 0.25; 95% CI, 0.11-0.56).

Promoting weekend high-intensity workouts may be beneficial for older adults to lower sarcopenia risk.

High-protein diets (1.6 or 3.2 g kg−1 d−1) combined with resistance training (RT) or concurrent training (CT) for 16 weeks had no adverse effects on bone tissue parameters in resistance-trained males.

Practitioners can recommend high-protein diets for resistance-trained individuals without concern for negative effects on bone health.

There were significant time effects noted for the BMD of the pelvis and the BMC of the right ribs.

Practitioners should monitor bone health parameters over time in resistance-trained individuals on high-protein diets.

Approximately 1-in-10 participants met the resistance training guidelines.

Only a small fraction of the population adheres to recommended resistance training guidelines.

The increase in body protein mass due to the energy surplus was correlated with an increase in fat mass (r = 0.820, p = 0.002).

Increased body fat may play a role in promoting body protein mass gain.

Continuous glucose monitoring (CGM) can help patients better manage their metabolic control during exercise.

Incorporating CGM technology can enhance exercise safety and effectiveness for diabetic patients.

The study will evaluate both quantitative and qualitative effects of the SALUD program.

The dual evaluation approach can provide comprehensive insights for T2DM interventions.

A gradual decrease in total body fat and no decrease in appendicular lean mass (ALM) are significantly independently associated with higher cognitive scores compared with other trajectories.

Weight loss strategies should focus on reducing body fat while preserving lean mass to support cognitive health.

Differences in cognitive score were large for sarcopenia, but not for obesity.

Addressing sarcopenia may be crucial for maintaining cognitive function in this population.

Weight loss approaches that preserve ALM and function may lead to reduced cognitive decline compared with weight loss alone.

Practitioners should consider strategies that maintain lean mass during weight loss to support cognitive health.

The intervention group exhibited improved self-efficacy (Z = 4.06, P < 0.001) compared to the control group.

Enhancing self-efficacy through targeted interventions can support behavior change in physically inactive young adults.

Responders to the PF regimen exhibited enhanced metabolic flexibility compared to non-responders.

Personalized dietary interventions may enhance metabolic flexibility in patients with T2D.

Glucagon-like peptide 1 receptor agonists consistently reduce three-point major adverse cardiovascular events (MACE) in patients with overweight, obesity, and established cardiovascular disease (CVD) with and without diabetes.

Practitioners can consider glucagon-like peptide 1 receptor agonists as effective treatments for reducing cardiovascular events in eligible patients.